Neuropathy News and Research RSS Feed - Neuropathy News and Research

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare. [More]
SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]
Utz Quality Foods donates $2 million toward breast cancer survivorship program

Utz Quality Foods donates $2 million toward breast cancer survivorship program

Utz Quality Foods Inc., Executive Chairman Michael Rice and his wife Jane, a breast cancer survivor, have donated $2 million toward a breast cancer survivorship program at the Johns Hopkins Kimmel Cancer Center. [More]
ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). [More]
New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group. [More]
ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL). [More]
NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the marketing launch in Japan of NC-stat® DPNCheck®. [More]
Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Corneal nerve fiber assessment has potential to monitor peripheral neuropathy induced by HIV

Corneal nerve fiber assessment has great potential as a tool to diagnose and monitor peripheral neuropathy induced by HIV, say scientists at the Johns Hopkins University School of Medicine. [More]
Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging. [More]
Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]

Study links nerve damage after hip surgery to inflammatory neuropathy

A recent Mayo Clinic Proceedings article links some nerve damage after hip surgery to inflammatory neuropathy. Historically, nerve damage from hip surgery has been attributed to mechanical factors caused by anesthesiologists or surgeons, such as positioning of the patient during surgery or direct surgical injury of the nerves. [More]
MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. [More]
Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

A CONSULTANT who first described how diabetic nerve damage is caused by impaired circulation of the nerves has been awarded one of the most coveted international prizes in medicine in recognition of his outstanding contribution to the field. [More]
Women who had chemotherapy less likely to be employed 4 years later

Women who had chemotherapy less likely to be employed 4 years later

Nearly one-third of breast cancer survivors who were working when they began treatment were unemployed four years later. Women who received chemotherapy were most affected, according to a new study from the University of Michigan Comprehensive Cancer Center. [More]
Research roundup: Structural concerns in ACOs; public's view of mandated contraception coverage

Research roundup: Structural concerns in ACOs; public's view of mandated contraception coverage

The Medicare Accountable Care Organization (ACO) programs reward participating health care provider groups that achieve slower spending growth and high quality of care. [More]
Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

New research published today out of the University of Calgary's Hotchkiss Brain Institute uncovers a mechanism to promote growth in damaged nerve cells as a means to restore connections after injury. Dr. Doug Zochodne and his team have discovered a key molecule that directly regulates nerve cell growth in the damaged nervous system. [More]